Niagen Bioscience (NAGE) announced that its board of directors has authorized an increase to the company’s previously disclosed share repurchase program, raising the total authorization from $10M to $20M of the company’s outstanding common stock. Through March 17, the company has repurchased approximately $2.6M of its common stock under the share repurchase program.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- VGT vs. VOO vs. VDC: Which Vanguard ETF Has More Upside in 2026?
- Niagen Bioscience price target lowered to $13 from $14 at Canaccord
- Niagen Bioscience: Tru Niagen‑Driven Beat, Durable Double‑Digit Growth Outlook, and FDA Litigation Upside Support Buy Rating
- Niagen Bioscience Reports Strong 2025 Results, Strategic Shift
- Niagen Bioscience sees FY26 revenue up 10%-15%, implying $142.3M-$148.8M